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SUMMARY 
Background: Human immunodeficiency virus (HIV) 
and Hepatitis B virus (HBV) share similar routes of 
transmission, making it possible for an individual to 
have a co-infection. HBV infection is well known to be 
a major cause of chronic liver diseases worldwide. The 
aim of this study was to determine the prevalence of 
HBV infection among HIV infected HAART naïve 
patients and investigate the effect of co-infection on 
CD4 count and liver function. 
Study design: This was a hospital based descriptive 
cross sectional study of one hundred consecutive thera-
py-naive HIV-infected individuals. The CD4 count, 
Hepatitis B surface antigen, Serum albumin, total Pro-
tein, and liver enzymes were determined using standard 
techniques. 
Results: The prevalence of HIV and HBV co-infection 
was 37%. The mean serum ALT and ALP were signifi-
cantly higher in the co- infected patients (P-values 
<0.05). The mean CD4 count of the mono infected 
patients was significantly higher (p-value of 0.014). 
The mean serum ALT, AST and ALP of mono and co-
infected patients with CD4 count<200/µl were signifi-
cantly higher than those with count ≥ 200 cells/µl. (p-
value of <0.01). The mean ALT and AST of the co -
infected patients and all patients with CD4 count <200 
cells/µl were higher than the normal reference range. 
Conclusion: Approximately one third of HIV positive 
patients had hepatitis B virus co-infection.  Co-
infection and CD4 count <200 cells/µl are likely to 
result in abnormal ALT and AST. We recommend 
those co-infected patients and those with CD4 count 
<200 cells/µl should be given non-hepatotoxic an-
tiretroviral drug. 
 




Human immunodeficiency virus (HIV) and Hepatitis B 
virus (HBV) share similar routes of transmission, mak-
ing it possible for an individual to have co-infection. 
The common routes of transmission vary from place to 
place depending on the degree of endemicity of HBV.  
In areas of low endemicity, such as North America, 
Australia and Europe, HBV and HIV infection are usu-
ally acquired in adulthood through sexual or percuta-
neous transmission. In countries with intermediate and 
high HBV endemicity like Nigeria, the main routes of 
transmission of HBV and HIV are vertical in children 
and through sexual intercourse in adults. The preva-
lence of chronic co-infection among HIV-infected in-
dividuals is around 5-7% and 10-20% respectively in 
countries with low and those with intermediate/high 
HBV endemicity respectively.1-4 
 
Hepatitis B virus infection is a major cause of chronic 
liver diseases including cirrhosis and hepatocellular 
carcinoma worldwide. The progression of hepatic 
complications from HBV infection is accelerated in 
patients co-infected with HIV.5, 6 This is particularly so 
in HIV infected men with very low CD4 count. 7In 
addition, HIV infected individuals are more likely to 
lose previously developed protective anti-HBs antibody 
and develop acute hepatitis B infection; this risk is also 
associated with lower CD4 counts.8 The risk of hepato-
cellular carcinoma (HCC) in HIV infected patients who 
are co-infected with hepatitis B virus is also increased 
in individuals with lower CD4 counts.9 
 
Hepatic toxicity is a common complication in HIV-
infected patients on Highly Active Antiretroviral Ther-
apy (HAART).10 Patients who had viral hepatitis in 
addition to HIV were found to be about 4 times more 
likely to develop severe hepatic toxicity associated 
with antiretroviral drug.  
 
 




This has been attributed to HAART induced immune 
reconstitution inflammatory syndrome (IRIS).11,12 Be-
cause of the HAART induced IRIS which usually leads 
to worsening of liver disease including hepatic de-
compensation, the actual effect of HBV and HIV co-
infection on liver function is best studied in HAART 
naive patients.  
 
The aim of this study was to determine the prevalence 
of HBV infection among HIV-infected HAART naive 
patients and investigate the effect of co-infection on 
CD4 count and liver function of the patients. 
 
PATIENTS AND METHODS 
Patients included in this study were the first 100 con-
secutive therapy-naive HIV- infected individuals at-
tending the HAART clinic at University of Ilorin 
Teaching Hospital, Ilorin between January and Decem-
ber 2010. University of Ilorin Teaching Hospital Ethi-
cal Review Committee which is a member of the Na-
tional Health Research Ethics Council approved the 
study protocol. Written Informed consent of the partic-
ipants was equally obtained. Patients that did not con-
sent to participate in the study were excluded. This 
research received no specific grant from any funding 
agency in the public, commercial, or not-for-profit sec-
tors. There is no other conflict of interest whatsoever. 
 
HIV positivity was diagnosed by positive reactions to 
two different enzyme linked immunosorbent assays 
(ELISA). Hepatitis B surface antigen test was done 
using ELISA method. All the ELISA assays were done 
using kits manufactured by Bio-Rad Laboratories, Inc., 
Berkeley, California. The CD4 cell count was deter-
mined using Dynal T4 Quant (Dynal Biotech ASA, 
Oslo, Norway). Laboratory assessment of liver func-
tions was determined by liver Enzymes - mainly Ala-
nine amino transferase (ALT), Aspartate amino trans-
ferase (AST), Alkaline phosphtase (ALP) and albumin 
as a synthetic function. 
 
Serum Albumin and Total protein were determined 
with Randox kit (Randox Laboratory limited, Ardmore, 
UK) using the Bromo Cresol Green (BCG) 13 and Biu-
ret14 methods respectively. Normal ranges were 35-
50g/l and 60-80g/l respectively. ALT, AST and ALP 
were determined with Agappe Kit (Agappe Diagnos-
tics, Switzerland GmbH)15 Normal ranges were 0-
15IU/L, 0-23IU/L and 21-91IU/L respectively.Data 
was analysed using SPSS version 15. Statistical analy-
sis of mean and standard deviation were used for the 
numeric variables. Mean of the CD4 count and the var-
ious parameters of liver function test of the Hepatitis B 
surface antigen (HBsAg) positive and negative patients 
were compared by the student t-test. Differences were 
regarded as significant when P≤ 0.05. 
RESULTS 
One hundred HIV patients (35 males and 65 females) 
aged 37±9 years (mean± SD) were recruited for this 
study. Thirty seven (37%) were hepatitis B positive 
while 63(63%) were negative. Twenty four (64.9%) of 
the HBsAg patients were females while 13(35.1%) 
were males.  Majority i.e. 52% of the patients present-
ed at stage 3 and only 20% presented at stage 1 (Table 
1). 
Effect of Hepatitis B virus co-infection on CD4 cell 
count and liver function of HIV infected patients 
The mean CD4 count of all the patients was 212 
±188/µl. The mean serum levels for ALT, AST, ALP, 
total protein and albumin for the study population were 
17±23IU/L, 25± 24IU/L, 56± 64IU/L, 75±9g/l and 
38±7g/l respectively.  
 
Table 1 Stage of disease at diagnosis and HBsAg sta-
tus 







  Negative Positive  
 1 15(15) 5(5) 20(20) 
  2 8(8) 7(7) 15(15) 
  3 32(32) 20(20) 52(52) 
  4 8(8) 5(5) 13(13) 
Total 63(63) 37(37) 100(100) 
 
The mean levels of liver enzymes, serum albumin and 
total proteins of the HIV mono infected patients were 
all within the normal reference ranges. In  the co-
infected patients, ALT and AST were higher than nor-
mal but the other parameters were within the normal 
reference ranges. The mean serum level of ALT and 
ALP were significantly higher in the co infected pa-
tients than in the HIV mono infected patients, P-values 
of 0.043 and 0.042 respectively.  
 
Table 2 Biochemical parameter and CD4 count in 










ALT(UI/L) 13.86 ±19.8 23.32 ± 26.1 9.4672 0.043 
AST(UI/L) 21.95±  23.5 29.84 ±25.1 7.8855 0.118 
ALP(UI/L) 45.76± 55.2 72.95 ±75.3 27.1878 0.042 
Total protein 
(g/l) 
75.68± 11.6 74.50 ±9.7 1.1825 0.606 








Normal reference values: Serum albumin (35-50g/l), Total protein 








The higher level of AST among co infected patients 
compared to the HIV mono infected patients was not 
statistically significant (p-value of 0.11) and there was 
no significant difference in the levels of total protein 
and albumin between the co infected and mono infect-
ed patients (Table 2)The mean CD4 count of the mono 
infected patients was significantly higher than that of 
the co-infected patients (p-value of 0.014). Table 2 
 
The mean levels of all the liver enzymes, serum albu-
min and total proteins of the all HIV  infected patients 
with CD4 count ≥ 200/µl were all within the normal 
reference ranges for the laboratory. For those with CD4 
count below 200/µl the mean ALT and AST were 
higher than normal but the other parameters were with-
in the normal reference ranges.  
 
Table 3 Biochemical parameters in patients with CD4 















ALT(UI/L) >= 200 37 13.000 11.5326 -6.9206  












>= 200 37 17.946 16.4805 -10.9906 
 
< 200 63 28.937 27.2041  0.002 
ALP(UI/L) 
  
>= 200 36 43.944 45.2364 -18.8175 
 





      
36 
   
72.722 
      
10.0644 -3.9762 
 
 (g/l) < 200 63 76.698 11.1668  0.637 
       
Albumin 
(g/l) 
>= 200 36 37.750 6.3308 -0.1310 0.839 
 < 200 63 37.619 7.0400   
Normal reference values: Serum albumin (35-50g/l), Total protein 
(60-80g/l), ALT (0-15IU/L), AST (0-23IU/L) and ALP(21-91IU/L) 
 
The mean serum level of ALT, AST and ALP of pa-
tients with CD4 count below 200/µl were significantly 
higher than the mean of those with CD4 count ≥ 
200/µl. (p-value of <0.01 in each case) Table 3 
 
The mean level of AST of the male co-infected patients 
was significantly higher than their female counterparts 
(p-value of 0.007) but there was no significant differ-
ence in their ALT, ALP, serum albumin and total pro-
tein level.  
 
Among the HIV mono-infected patients significant 
difference was found only in the ALT level in which 
case the mean value in males was significantly higher 
than in female ( p-value of 0.047) (Table 4) 
 
Table 4 Sex comparison of biochemical parameters 
among co-infected and mono-infected patients 
param-
eters 
       Co-infected patients      Mono-infected patients 





















































Hepatitis B virus is a major cause of chronic liver dis-
ease worldwide. Hepatic toxicity is also a well-known 
complication of treatment of HIV infection with 
HAART. Accurate assessment of HBV infection in 
HIV co-infected individuals is necessary in order to 
make therapeutic decisions.6 World Health Organiza-
tion (WHO) advocates HBsAg testing especially in 
areas of high HBV prevalence, but additional testing 
for HBV markers such as HBeAg and HBV DNA and 
tests to assess stage of liver disease (e.g. liver enzymes, 
liver biopsy, etc) may not be widely available in many 
resource limited countries.16  
 
In most of the centres where HIV/AIDS patients are 
being managed in Nigeria the HBsAg and assay of 
liver enzymes are done routinely before commence-
ment of HAART. This is to help the physician to de-
cide on the appropriate regimen in terms of avoiding 
those that are hepatotoxic in patients who already have 
derangement of the liver function and also the use of 
drugs that are also effective against HBV for HBsAg 
positive patients. 
 
The prevalence of HBV infection among HIV infected 
HAART naive patients in this study was 37%. This is 
higher than the prevalence in other countries with high 
HBV endemicity. 1-4 
 
This study has shown that the level of serum ALT and 
ALP is higher in HIV and HBV co-infected patients 
compared to HIV mono-infected patients. This is con-
sistent with a previous study done in Nigeria and South 
Tamil Nadu .17, 18  
 
This study has also shown that CD4 count of the HIV 
mono-infected patients was significantly higher than 
that of the patients co-infected with HBV.  
 
 




Furthermore, mean serum level of ALT, AST and ALP 
of patients with CD4 count below 200/µl were signifi-
cantly higher than in those with CD4 count ≥ 200/µl. In 
a prospective longitudinal cohort study with subjects 
recruited from US, Australia and Thailand, it was 
found that the prevalence of hepatotoxicity at baseline 
was about 13% and that CD4 count < 200 cells/mm3 
and HBV DNA > 2000 IU/ml were significantly asso-
ciated with an increased risk of significant hepatotoxi-
city among HIV/HBV co-infected people on long-term 
HAART.19 
 
The serum levels of ALT and AST among mono- and 
co-infected patients respectively were significantly 
higher among male patients than in female patients. 
This difference was much more significant among the 
co-infected patients and therefore confirms previous 
studies that suggested that HIV infection accelerated 
the progression to hepatic complications in HBV in-
fected men. 5, 6 
 
Routine estimation of Alanine aminotransferase (ALT) 
is an inexpensive and non-invasive means of assessing 
liver disease as it reflects the activity of hepatotropic 
viruses and status of liver during therapy with various 
hepatotoxic drugs. Even though it is well known that 
ALT may even be normal in the presence of advanced 
liver disease, in resource limited countries like Nigeria 
it still remains the affordable test in the assessment of 
liver function in the management of HIV/AIDS pa-
tients.  
 
Elevated ALT at baseline is an indication that the liver 
is already compromised and so drugs that are hepato-
toxic will have to be avoided in order not to further 
compromise the liver function. Those with co-infection 
with HBV are usually given drugs that are also effec-
tive for treatment of HBV. 
 
Baseline CD4 count which used to be a standard re-
quirement for commencement of antiretroviral therapy 
may also be used as a surrogate test for liver function 
especially in co-infected patients. So that even if the 
ALT is normal a low CD4 count below 200 may be a 
signal for performing more sensitive or invasive test to 
assess the function of the liver. 
 
CONCLUSION 
In conclusion, the prevalence of HBV infection among 
HIV infected HAART naive patients in this study were 
higher than in previous studies. Hepatitis B virus co-
infected HIV positive patients are more likely to have 
abnormal liver function test than the mono-infected 
patients. HIV infected patients with CD4 below 200/µl 
are also more likely to have abnormal liver function 
than those with CD4 count above 200cells/µl.  
We recommend that hepatitis B virus co-infected HIV 
positive patients should be given first-line antiretroviral 
drugs that are non- hepatotoxic. Patients with CD4 
count below 200cells/µl should also be given non hepa-
totoxic antiviral drugs regardless of their HBsAg sta-
tus.   
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